

Aslam H Anis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7335753/publications.pdf>

Version: 2024-02-01

123
papers

5,192
citations

94433

37
h-index

95266

68
g-index

125
all docs

125
docs citations

125
times ranked

5336
citing authors

#	ARTICLE	IF	CITATIONS
1	People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses. <i>Journal of Infectious Diseases</i> , 2023, 227, 838-849.	4.0	31
2	Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. <i>Npj Vaccines</i> , 2022, 7, 28.	6.0	64
3	Distinguishing symptom patterns in adults newly diagnosed with cancer: a latent class analysis. <i>Journal of Pain and Symptom Management</i> , 2022, 64, 146-155.	1.2	5
4	Patient-provider communication about medication cost in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 93-100.	2.2	6
5	When does the use of individual patient data in network meta-analysis make a difference? A simulation study. <i>BMC Medical Research Methodology</i> , 2021, 21, 21.	3.1	7
6	Comparing the use of aggregate data and various methods of integrating individual patient data to network meta-analysis and its application to first-line ART. <i>BMC Medical Research Methodology</i> , 2021, 21, 60.	3.1	2
7	Valuation of Lost Productivity in Caregivers: A Validation Study. <i>Frontiers in Psychology</i> , 2021, 12, 727871.	2.1	4
8	CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study. <i>BMJ Open</i> , 2021, 11, e054208.	1.9	7
9	A Hierarchical Bayes Approach to Modeling Heterogeneity in Discrete Choice Experiments: An Application to Public Preferences for Prenatal Screening. <i>Patient</i> , 2020, 13, 211-223.	2.7	7
10	Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis. <i>EClinicalMedicine</i> , 2020, 28, 100573.	7.1	54
11	Health-care practitioners'™ preferences for the return of secondary findings from next-generation sequencing: a discrete choice experiment. <i>Genetics in Medicine</i> , 2020, 22, 2011-2019.	2.4	9
12	Factors associated with drug shortages in Canada: a retrospective cohort study. <i>CMAJ Open</i> , 2020, 8, E535-E544.	2.4	13
13	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 1583-1584.	5.6	0
14	The Impact of Tiered-Pricing Framework on Generic Entry in Canada. <i>International Journal of Health Policy and Management</i> , 2020, , .	0.9	2
15	Role of Nonsteroidal Antiinflammatory Drugs in the Association Between Osteoarthritis and Cardiovascular Diseases: A Longitudinal Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 1835-1843.	5.6	56
16	Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh. <i>International Journal of Drug Policy</i> , 2019, 74, 69-75.	3.3	5
17	Treatment with injectable hydromorphone: Comparing retention in double blind and open label treatment periods. <i>Journal of Substance Abuse Treatment</i> , 2019, 101, 50-54.	2.8	23
18	Cost-effectiveness of prenatal screening and diagnostic strategies for Down syndrome: A microsimulation modeling analysis. <i>PLoS ONE</i> , 2019, 14, e0225281.	2.5	16

#	ARTICLE	IF	CITATIONS
19	Early cost-effectiveness modeling for better decisions in public research investment of personalized medicine technologies. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 7-19.	1.4	7
20	Attitudes toward prenatal screening for chromosomal abnormalities: A focus group study. <i>Women and Birth</i> , 2019, 32, 364-371.	2.0	6
21	Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial. <i>Addiction</i> , 2018, 113, 1264-1273.	3.3	33
22	The design and rationale of SAVE BC: The Study to Avoid CardioVascular Events in British Columbia. <i>Clinical Cardiology</i> , 2018, 41, 888-895.	1.8	11
23	Output from the CIHR Canadian HIV Trials Network international postdoctoral fellowship for capacity building in HIV clinical trials. <i>HIV/AIDS - Research and Palliative Care</i> , 2018, Volume 10, 151-155.	0.8	0
24	Influenza vaccination for HIV-positive people: Systematic review and network meta-analysis. <i>Vaccine</i> , 2018, 36, 4077-4086.	3.8	14
25	Valuing productivity loss due to absenteeism: firm-level evidence from a Canadian linked employer-employee survey. <i>Health Economics Review</i> , 2017, 7, 3.	2.0	19
26	A Practical ANOVA Approach for Uncertainty Analysis in Population-Based Disease Microsimulation Models. <i>Value in Health</i> , 2017, 20, 710-717.	0.3	4
27	Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2017, 176, 55-62.	3.2	30
28	Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2017, 167, 8.	3.9	45
29	The impact of price-cap regulations on market entry by generic pharmaceutical firms. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 231-238.	1.4	5
30	Do Biologic Therapies for Rheumatoid Arthritis Offset Treatment-Related Resource Utilization and Cost? A Review of the Literature and an Instrumental Variable Analysis. <i>Current Rheumatology Reports</i> , 2017, 19, 54.	4.7	9
31	Men's and women's response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2017, 12, 25.	2.2	27
32	Adherence to Antitumor Necrosis Factor Use Recommendations in Spondyloarthritis: Measurement and Effect in the DESIR Cohort. <i>Journal of Rheumatology</i> , 2017, 44, 1436-1444.	2.0	1
33	Validation of Administrative Osteoarthritis Diagnosis Using a Clinical and Radiological Population-Based Cohort. <i>International Journal of Rheumatology</i> , 2016, 2016, 1-7.	1.6	20
34	Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence. <i>JAMA Psychiatry</i> , 2016, 73, 447.	11.0	168
35	Impact of etanercept tapering on work productivity in patients with early rheumatoid arthritis: results from the PRIZE study. <i>RMD Open</i> , 2016, 2, e000222.	3.8	5
36	The Impact of Price-cap Regulations on Exit by Generic Pharmaceutical Firms. <i>Medical Care</i> , 2016, 54, 884-890.	2.4	17

#	ARTICLE	IF	CITATIONS
37	Making smart investment decisions in clinical research. <i>Trials</i> , 2015, 16, 590.	1.6	3
38	Multiattribute health utility scoring for the computerized adaptive measure CAT-5D-QOL was developed and validated. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 1213-1220.e6.	5.0	4
39	Systematic Review of Cost-Effectiveness Analyses of Treatments for Psoriasis. <i>Pharmacoeconomics</i> , 2015, 33, 327-340.	3.3	20
40	Predictors of non-use of illicit heroin in opioid injection maintenance treatment of long-term heroin dependence. <i>Addictive Behaviors</i> , 2015, 41, 81-86.	3.0	6
41	A Ban on "Private Label" Generic Pharmaceuticals: Legal and Economic Context. <i>International Journal of the Economics of Business</i> , 2015, 22, 219-229.	1.7	1
42	Illness related wage and productivity losses: Valuing "presenteeism". <i>Social Science and Medicine</i> , 2015, 147, 62-71.	3.8	30
43	Estimating the monetary value of the annual productivity gained in patients with early rheumatoid arthritis receiving etanercept plus methotrexate: interim results from the PRIZE study. <i>RMD Open</i> , 2015, 1, e000042-e000042.	3.8	13
44	A chance to stop and breathe: participants' experiences in the North American Opiate Medication Initiative clinical trial. <i>Addiction Science & Clinical Practice</i> , 2014, 9, 21.	2.6	23
45	High levels of opioid analgesic co-prescription among methadone maintenance treatment clients in British Columbia, Canada: Results from a population-level retrospective cohort study. <i>American Journal on Addictions</i> , 2014, 23, 257-264.	1.4	24
46	Risk of Type 2 Diabetes among Osteoarthritis Patients in a Prospective Longitudinal Study. <i>International Journal of Rheumatology</i> , 2014, 2014, 1-7.	1.6	28
47	Differential long-term outcomes for voluntary and involuntary transition from injection to oral opioid maintenance treatment. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2014, 9, 23.	2.2	12
48	Health-Related Productivity Loss: NICE to Recognize Soon, Good to Discuss Now. <i>Pharmacoeconomics</i> , 2014, 32, 425-427.	3.3	8
49	Optimal timing of influenza vaccination in patients with human immunodeficiency virus: A Markov cohort model based on serial study participant hemoagglutination inhibition titers. <i>Vaccine</i> , 2014, 32, 677-684.	3.8	4
50	Osteoarthritis Incidence and Trends in Administrative Health Records from British Columbia, Canada. <i>Journal of Rheumatology</i> , 2014, 41, 1147-1154.	2.0	20
51	Factors associated with pretreatment and treatment dropouts: comparisons between Aboriginal and non-Aboriginal clients admitted to medical withdrawal management. <i>Harm Reduction Journal</i> , 2013, 10, 38.	3.2	14
52	Changes in the Characteristics and Levels of Comorbidity Among New Patients Into Methadone Maintenance Treatment Program in British Columbia During Its Expansion Period From 1998 to 2006. <i>Substance Use and Misuse</i> , 2013, 48, 671-682.	1.4	8
53	Therapies for Active Rheumatoid Arthritis after Methotrexate Failure. <i>New England Journal of Medicine</i> , 2013, 369, 307-318.	27.0	313
54	Cost-Effectiveness of Newer Antiretroviral Drugs in Treatment-Experienced Patients With Multidrug-Resistant HIV Disease. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 382-391.	2.1	11

#	ARTICLE	IF	CITATIONS
55	The relationship between osteoarthritis and cardiovascular disease in a population health survey: a cross-sectional study. <i>BMJ Open</i> , 2013, 3, e002624.	1.9	70
56	Risk of Cardiovascular Disease in Patients With Osteoarthritis: A Prospective Longitudinal Study. <i>Arthritis Care and Research</i> , 2013, 65, 1951-1958.	3.4	90
57	High levels of opioid analgesic co-prescription among methadone maintenance treatment clients in British Columbia, Canada: Results from a population-level retrospective cohort study. <i>American Journal on Addictions</i> , 2013, 23, n/a-n/a.	1.4	1
58	Does achieving clinical response prevent work stoppage or work absence among employed patients with early rheumatoid arthritis?. <i>Rheumatology</i> , 2012, 51, 270-274.	1.9	13
59	Factors associated with absenteeism, presenteeism and activity impairment in patients in the first years of RA. <i>Rheumatology</i> , 2012, 51, 375-384.	1.9	57
60	Effect of Treatment Interruption and Intensification of Antiretroviral Therapy on Health-Related Quality of Life in Patients with Advanced HIV. <i>Medical Decision Making</i> , 2012, 32, 70-82.	2.4	12
61	An update on the measurement of productivity losses due to rheumatoid diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 585-597.	3.3	7
62	Development of a Composite Questionnaire, the Valuation of Lost Productivity, to Value Productivity Losses: Application in Rheumatoid Arthritis. <i>Value in Health</i> , 2012, 15, 46-54.	0.3	54
63	Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. <i>Cmaj</i> , 2012, 184, E317-E328.	2.0	82
64	Canadian Valuation of EQ-5D Health States: Preliminary Value Set and Considerations for Future Valuation Studies. <i>PLoS ONE</i> , 2012, 7, e31115.	2.5	166
65	Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial. <i>PLoS ONE</i> , 2011, 6, e14764.	2.5	16
66	Measuring Time Input Loss Among Patients With Rheumatoid Arthritis. <i>Journal of Occupational and Environmental Medicine</i> , 2011, 53, 530-536.	1.7	52
67	Measuring and valuing productivity loss due to poor health: A critical review. <i>Social Science and Medicine</i> , 2011, 72, 185-192.	3.8	245
68	Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2011, 30, 9-18.	2.2	20
69	The economic burden of rheumatoid arthritis: beyond health care costs. <i>Clinical Rheumatology</i> , 2011, 30, 25-32.	2.2	48
70	Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , 2011, 22, 65-74.	2.2	32
71	The Cost-Effectiveness and Value of Information of Three Influenza Vaccination Dosing Strategies for Individuals with Human Immunodeficiency Virus. <i>PLoS ONE</i> , 2011, 6, e27059.	2.5	14
72	Ontario's plunging price-caps on generics: deeper dives may drown some drugs. <i>Open Medicine</i> , 2011, 5, e149-52.	1.5	3

#	ARTICLE	IF	CITATIONS
73	Work Productivity Among Employed Canadians With Arthritis. <i>Journal of Occupational and Environmental Medicine</i> , 2010, 52, 872-877.	1.7	20
74	Productivity Loss Due to Presenteeism Among Patients with Arthritis: Estimates from 4 Instruments. <i>Journal of Rheumatology</i> , 2010, 37, 1805-1814.	2.0	102
75	Trends in methadone maintenance treatment participation, retention, and compliance to dosing guidelines in British Columbia, Canada: 1996-2006. <i>Journal of Substance Abuse Treatment</i> , 2010, 39, 22-31.	2.8	92
76	The quality of eight health status measures were compared for chronic opioid dependence. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 1132-1144.	5.0	33
77	The effect of motivational status on treatment outcome in the North American Opiate Medication Initiative (NAOMI) study. <i>Drug and Alcohol Dependence</i> , 2010, 111, 161-165.	3.2	39
78	Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: Rationale and design of the NAOMI study. <i>Clinical Trials</i> , 2009, 6, 261-271.	1.6	36
79	Measuring Worker Productivity: Frameworks and Measures. <i>Journal of Rheumatology</i> , 2009, 36, 2100-2109.	2.0	90
80	Quality of Life of Patients With Advanced HIV/AIDS: Measuring the Impact of Both AIDS-Defining Events and Non-AIDS Serious Adverse Events. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 631-639.	2.1	44
81	Efficacy of Systemic Treatments for Moderate to Severe Plaque Psoriasis: Systematic Review and Meta-Analysis. <i>Dermatology</i> , 2009, 219, 209-218.	2.1	87
82	Diacetylmorphine versus Methadone for the Treatment of Opioid Addiction. <i>New England Journal of Medicine</i> , 2009, 361, 777-786.	27.0	303
83	Proportional Hazards Frailty Models for Recurrent Methadone Maintenance Treatment. <i>American Journal of Epidemiology</i> , 2009, 170, 783-792.	3.4	85
84	The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. <i>Rheumatology</i> , 2009, 48, 1283-1289.	1.9	58
85	The economics of treatment in early rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 83-92.	3.3	17
86	Health insurance and out-of-pocket expenses. <i>Arthritis and Rheumatism</i> , 2009, 61, 1467-1469.	6.7	0
87	The concurrent validity and responsiveness of the health utilities index (HUI 3) among patients with advanced HIV/AIDS. <i>Quality of Life Research</i> , 2009, 18, 815-824.	3.1	10
88	Impact of the recall period on measuring health utilities for acute events. <i>Health Economics (United Kingdom)</i> , 2009, 23, 117-128.	1.7	18
89	Health state utility values: A description of their development and application for rheumatic diseases. <i>Arthritis and Rheumatism</i> , 2008, 59, 1018-1026.	6.7	24
90	The Cost-Effectiveness of Three Strategies for the Surgical Treatment of Symptomatic Primary Hyperparathyroidism. <i>Annals of Surgical Oncology</i> , 2008, 15, 2653-2660.	1.5	16

#	ARTICLE	IF	CITATIONS
91	Economic Evaluations in Rheumatoid Arthritis. <i>Pharmacoeconomics</i> , 2008, 26, 395-408.	3.3	27
92	Factors Associated with Seeking Readmission among Clients Admitted to Medical Withdrawal Management. <i>Substance Abuse</i> , 2008, 29, 65-72.	2.3	18
93	Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 1729-36.	2.0	21
94	Medical withdrawal management in Vancouver: Service description and evaluation. <i>Addictive Behaviors</i> , 2007, 32, 1043-1053.	3.0	5
95	The impact of cost sharing of prescription drug expenditures on health care utilization by the elderly: Own- and cross-price elasticities. <i>Health Policy</i> , 2007, 82, 340-347.	3.0	48
96	Factors Associated with Pretreatment and Treatment Dropouts Among Clients Admitted to Medical Withdrawal Management. <i>Journal of Addictive Diseases</i> , 2007, 26, 77-85.	1.3	16
97	Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 57, 963-971.	6.7	68
98	Impact of welfare cheque issue days on a service for those intoxicated in public. <i>Harm Reduction Journal</i> , 2007, 4, 12.	3.2	15
99	A Cost-Utility Analysis of Losartan versus Atenolol in the Treatment of Hypertension with Left Ventricular Hypertrophy. <i>Pharmacoeconomics</i> , 2006, 24, 387-400.	3.3	15
100	Do visual analogue scale (VAS) derived standard gamble (SG) utilities agree with Health Utilities Index utilities? A comparison of patient and community preferences for health status in rheumatoid arthritis patients. <i>Health and Quality of Life Outcomes</i> , 2006, 4, 25.	2.4	28
101	The Indirect Costs of Arthritis Resulting From Unemployment, Reduced Performance, and Occupational Changes While at Work. <i>Medical Care</i> , 2006, 44, 304-310.	2.4	173
102	Health economic evaluation: A primer for the practicing rheumatologist. <i>Arthritis and Rheumatism</i> , 2006, 55, 648-656.	6.7	15
103	A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. <i>Social Science and Medicine</i> , 2005, 60, 1571-1582.	3.8	333
104	Gaps in care for rheumatoid arthritis: A population study. <i>Arthritis and Rheumatism</i> , 2005, 53, 241-248.	6.7	201
105	Are indirect utility measures reliable and responsive in rheumatoid arthritis patients?. <i>Quality of Life Research</i> , 2005, 14, 1333-1344.	3.1	72
106	When patients have to pay a share of drug costs: effects on frequency of physician visits, hospital admissions and filling of prescriptions. <i>Cmaj</i> , 2005, 173, 1335-1340.	2.0	56
107	A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 519-529.	1.4	6
108	An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis. <i>Drugs</i> , 2005, 65, 473-496.	10.9	65

#	ARTICLE	IF	CITATIONS
109	Managing arthritis and employment: Making arthritis-related work changes as a means of adaptation. <i>Arthritis and Rheumatism</i> , 2004, 51, 909-916.	6.7	101
110	A Comparison of Four Indirect Methods of Assessing Utility Values in Rheumatoid Arthritis. <i>Medical Care</i> , 2004, 42, 1125-1131.	2.4	114
111	Lowering Generic Drug Prices. <i>Medical Care</i> , 2003, 41, 135-141.	2.4	31
112	Economic Evaluation of Propofol for Sedation of Patients Admitted to Intensive Care Units. <i>Anesthesiology</i> , 2002, 96, 196-201.	2.5	65
113	Why is calling an ACE an ACE so controversial? Evaluating reference-based pricing in British Columbia. <i>Cmaj</i> , 2002, 166, 763-4.	2.0	4
114	A Dog's Breakfast. <i>Medical Care</i> , 2001, 39, 315-326.	2.4	82
115	The effectiveness and toxicity of cyclosporin A in rheumatoid arthritis: longitudinal analysis of a population-based registry. <i>Arthritis and Rheumatism</i> , 2001, 45, 240-245.	6.7	25
116	Beyond Administrative Data: Characterizing Cardiorespiratory Disease Episodes Among Patients Visiting the Emergency Department. <i>Canadian Journal of Public Health</i> , 2000, 91, 107-112.	2.3	9
117	The Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV/AIDS. <i>Pharmacoeconomics</i> , 2000, 18, 393-404.	3.3	27
118	The social determinants of emergency department and hospital use by injection drug users in Canada. <i>Journal of Urban Health</i> , 1999, 76, 409-418.	3.6	93
119	Price regulation of pharmaceuticals in Canada. <i>Journal of Health Economics</i> , 1998, 17, 21-38.	2.7	28
120	Using Pharmacoeconomic Analysis to Make Drug Insurance Coverage Decisions. <i>Pharmacoeconomics</i> , 1998, 13, 119-126.	3.3	24
121	Modelling the Potential Economic Impact of Viral Load-Driven Triple Drug Combination Antiretroviral Therapy. <i>Pharmacoeconomics</i> , 1998, 13, 697-705.	3.3	25
122	Substitution Laws, Insurance Coverage, and Generic Drug Use. <i>Medical Care</i> , 1994, 32, 240-256.	2.4	24
123	Pharmaceutical Prices with Insurance Coverage and Formularies. <i>Canadian Journal of Economics</i> , 1992, 25, 420.	1.2	17